Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
29 September 2012
|
| In: |
BMC cancer
Year: 2012, Volume: 12 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-12-438 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1471-2407-12-438 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1471-2407-12-438 
|
| Author Notes: | Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños and Claus-Henning Köhne |
| Summary: | Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial. |
|---|---|
| Item Description: | Gesehen am 15.10.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-12-438 |